Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology/Urology
Disease Category: Kidney Cancer

Trial Information

Kidney Cancer Disease Study CRAD001L2201

Novartis is conducting this clinical research study to determine the effects of combining a Novartis investigational drug with an existing therapy, when treating people with metastatic clear cell carcinoma of the kidney (Kidney Cancer). An ?investigational drug? is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Participants will be required to visit their study site every two weeks for approximately two years. One group will be required to inject themselves three times a week and return to the study site every two weeks for an additional infusion treatment. Another group, will be required to take two tablets every day and return to the site every two weeks for an additional infusion treatment.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

Research Center
Located In:
Various Cities, NV

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.